Abstract
Introduction
Metastatic non clear cell renal cell carcinoma (nccRCC) is an heterogenous group,
usually excluded from phase 3 trials. We report real life data of prognosis and systemic
management of those patients.
Methods
We retrospectively included 102 metastatic nccRCC patients (unspecified papillary,
n = 10; type 1 and 2 papillary n = 10 and n = 32; translocation RCC, n = 9; chromophobe,
n = 14; collecting duct, n = 14) treated between 2006 and 2020. Objective response
rate (ORR), progression-free survival (PFS) and overall survival (OS) were evaluated.
Results
Among patients who underwent pathological review, 40.8% presented a complete histological
discordance. First line treatments were mainly tyrosine kinase inhibitor (60.8%),
combination including immunotherapy (7.8%) or combination of chemotherapy (13.7%).
Median ORR ranged from 0% in unspecified papillary RCC to 42.9% in type 1 papillary
RCC. Median PFS ranged from 2.9 months in collecting duct carcinoma to 10.9 months
in type 1 papillary RCC. Median OS ranged from 6.8 months in collecting duct carcinoma
to 29.1 months in MiT family translocation RCC. Thirty (29.4%) patients were included
in a treatment trial during their treatment course.
Conclusion
Metastatic nccRCC patients have variable prognosis due to heterogeneity of histological
subtypes. Their diagnosis and access to therapeutic innovation remain suboptimal.
Dedicated prospective trials are needed.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Genitourinary CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
REFERENCES
- Cancer statistics, 2018.CA Cancer J Clin. 2018; 68: 7-30
- Epidemiology of renal cell carcinoma [figure presented].Eur Urol [Internet]. 2019; 75: 74-84https://doi.org/10.1016/j.eururo.2018.08.036
- Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma.J Urol [Internet]. 2010; 183: 1309-1316https://doi.org/10.1016/j.juro.2009.12.035
- A postoperative prognostic nomogram for renal cell carcinoma.J Urol. 2001; 166: 63-67
- Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria.Cancer. 2013; 119: 2999-3006
- Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.N Engl J Med. 2019; 380: 1116-1127
- Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma.N Engl J Med. 2018; 378: 1277-1290
- Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma.N Engl J Med. 2021; 384: 829-841
- Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 1.Ann Oncol. 2021; 32: 422-423
- Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): A multicentre, open-label, randomised phase 2 trial.Lancet Oncol [Internet]. 2016; 17 (Available from:): 378-388https://doi.org/10.1016/S1470-2045(15)00515-X
- Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (espn): a randomized multicenter phase 2 trial.Eur Urol [Internet]. 2016; 69: 866-874https://doi.org/10.1016/j.eururo.2015.10.049
Evans AE, Angio GJD, Sather HN. Median Follow-Up in Clinical Trials. 2019;191–2.
- The 2016 WHO classification of tumours of the urinary system and male genital organs—part a: renal, penile, and testicular tumours.Eur Urol [Internet]. 2016; 70: 93-105https://doi.org/10.1016/j.eururo.2016.02.029
- Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology.J Clin Oncol. 2002; 20: 2376-2381
- Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.Ann Oncol. 2017; 28: 1339-1345
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2019; 30: 706-720
- Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non–clear cell renal cell carcinoma.J Clin Oncol. 2021; 39: 1029-1039
- Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.J Immunother Cancer. 2018; 6: 1-7
- Nivolumab for the treatment of patients with metastatic non-clear cell renal cell carcinoma (nccRCC): a single-institutional experience and literature meta-analysis.Oncologist. 2020; 25: 252-258
- Nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC): Safety and efficacy from CheckMate 920.J Clin Oncol. 2021; 39: 309
- Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy.Eur J Cancer. 2022; 171: 124-132
- Systemic therapy for chromophobe renal cell carcinoma: a systematic review.Urol Oncol. 2020; 38: 137-149https://doi.org/10.1016/j.urolonc.2019.11.006
- Phase II trial of cabozantinib plus nivolumab in patients with non–clear-cell renal cell carcinoma and genomic correlates.J Clin Oncol. 2022; 40: 2333-2341
- Sarcoma: Concordance between initial diagnosis and centralized expert review in a population-based study within three European regions.Ann Oncol [Internet]. 2012; 23 (Available from:): 2442-2449https://doi.org/10.1093/annonc/mdr610
Trpkov K, Hes O, Williamson SR, et al. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia [Internet]. Vol. 34, Modern Pathology. Springer US; 2021. 1392–1424 p. Available from: 10.1038/s41379-021-00779-w
Carlo MI, Khan N, Zehir A, Patil S, Ged Y, Redzematovic A. Original report abstract comprehensive genomic analysis of metastatic non – clear-cell renal cell carcinoma to identify therapeutic targets. 2020;1–18.
- Non-clear cell renal carcinomas: review of new molecular insights and recent clinical data.Cancer Treat Rev. 2021; 97
- A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.Lancet [Internet]. 2021; 397 (Available from): 695-703https://doi.org/10.1016/S0140-6736(21)00152-5
- Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets.Nat Commun [Internet]. 2016; 7: 1-10https://doi.org/10.1038/ncomms13131
- Characterization of clinical cases of collecting duct carcinoma of the kidney assessed by comprehensive genomic profiling.Eur Urol [Internet]. 2016; 70: 516-521https://doi.org/10.1016/j.eururo.2015.06.019
- Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.J Clin Oncol. 2020; 38: 5004
- Kidney cancer: from genes to therapy.Curr Probl Cancer [Internet]. 2021; 45 (Available from:)100773https://doi.org/10.1016/j.currproblcancer.2021.100773
- Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.J Clin Oncol. 2009; 27: 5794-5799
- Pazopanib for the treatment of non-clear cell renal cell carcinoma: a single-arm, open-label, multicenter, phase II study.Cancer Res Treat. 2018; 50: 488-494
- KEYNOTE-B61: open-label phase 2 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC).J Clin Oncol. 2021; 39: TPS4595
- Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival.JAMA Netw Open. 2021; 4: 1-11
- Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: results of the multicentre, open-label, single-arm, phase II AXIPAP trial.Eur J Cancer. 2020; 129: 107-116
- First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: A phase II study (SUPAP) by the French Genitourinary Group (GETUG).Ann Oncol. 2015; 26: 1123-1128
- Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis.Eur J Cancer. 2016; 69: 226-235
- Efficacy of savolitinib vs sunitinib in patients with MET -driven papillary renal cell carcinoma: the SAVOIR phase 3 randomized clinical trial.JAMA Oncol. 2020; 6: 1247-1255
- Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and/or sarcomatoid features.J Clin Oncol. 2020; 38: 63-70
Article info
Publication history
Published online: September 24, 2022
Accepted:
September 20,
2022
Received in revised form:
September 19,
2022
Received:
August 14,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2022 Elsevier Inc. All rights reserved.
